Intracystic injection of large surface area microparticle paclitaxel for chemoablation of intraductal papillary mucinous neoplasms: Insights from an expanded access protocol
Pancreatology · 2024
DOI: 10.1016/j.pan.2023.12.014 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Pancreatology, 2024. Verfasst von Somashekar G Krishna und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA. Electronic address…. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatitis, Pancreatic Neoplasms, Cysts. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
AIMS: A novel large surface area microparticle paclitaxel (LSAM-PTX) has unique properties of long retention in cystic spaces while maintaining high drug concentration. We prospectively evaluated the safety and response of EUS-guided fine needle injection (EUS-FNI) of LSAM-PTX to chemoablate branch duct (BD)-IPMNs. METHODS: Subjects diagnosed with BD-IPMNs exhibiting at least one worrisome criteria and considered non-surgical were enrolled in a multicenter clinical trial (NCT03188991) and subsequently included in an Expanded Access Protocol (EAP) where they received EUS-FNI of LSAM-PTX (15 mg/mL). RESULTS: Six BD-IPMNs measuring (mean ± SD) 3.18 ± 0.76 cm in diameter among 5 subjects (mean age: 66 years) were treated by EUS-FNI of LSAM-PTX. A mean of 4 doses of LSAM-PTX (mean dose/cyst: 73 ± 31 mg) were administered, and subjects were followed for up to 32 months. The mean volume reduction/cyst ranged from 42 to 89% (9.58 ± 5.1 ml to 2.2 ± 1.1 ml (p = 0.016)). The mean surface area reduction ranged from 31 to 83% (21.9 ± 8.7 cm2 to 5.7 ± 2.5 cm2 (p = 0.009)). Higher dosing-frequency of EUS-FNI of LSAM-PTX significantly correlated with a reduction in cyst volume (R2 = 0.87, p = 0.03) and surface area (R2 = 0.83, p = 0.04). Comparing pre- and post-ablation samples, molecular analysis of the cyst fluid revealed a loss of IPMN-associated mutations in 5 cases (83.3%), while reemergence was observed in 1 case and persistence in 1 case. Intracystic changes (fibrosis/calcification) were observed in 83.3% (n = 5). One subject developed mild acute pancreatitis (1 of 22 EUS-FNIs of LSAM-PTX). CONCLUSION: In this EAP, EUS-FNI of LSAM-PTX into BD-IPMNs was safe and resulted in volume and surface area reduction, morphological changes, and loss of pathogenic mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology, Hepatology and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA. Electronic address: Somashekar.krishna@osumc.edu.
- Division of Gastroenterology, Hepatology and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
- Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
- Department of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, OH, 43210, USA.
- James Molecular Laboratory, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA; Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
- Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
Zitieren
APA
Krishna, S. G., Ardeshna, D. R., Shah, Z. K., Hart, P. A., Culp, S., Jones, D., Chen, W., Papachristou, G. I., Han, S., Lee, P. J., Shah, H., Pawlik, T. M., Dillhoff, M., Manilchuk, A., Cloyd J, J. M., Ejaz, A., Fry, M., & Noonan, A. M. (2024). Intracystic injection of large surface area microparticle paclitaxel for chemoablation of intraductal papillary mucinous neoplasms: Insights from an expanded access protocol. Pancreatology. https://doi.org/10.1016/j.pan.2023.12.014
Vancouver
Krishna SG, Ardeshna DR, Shah ZK, Hart PA, Culp S, Jones D, et al. Intracystic injection of large surface area microparticle paclitaxel for chemoablation of intraductal papillary mucinous neoplasms: Insights from an expanded access protocol. Pancreatology. 2024. doi:10.1016/j.pan.2023.12.014
BibTeX
@article{Krishna2024,
author = {Krishna, Somashekar G and Ardeshna, Devarshi R and Shah, Zarine K and Hart, Phil A and Culp, Stacey and Jones, Dan and Chen, Wei and Papachristou, Georgios I and Han, Samuel and Lee, Peter J and Shah, Hamza and Pawlik, Timothy M and Dillhoff, Mary and Manilchuk, Andrei and Cloyd J, Jordan M and Ejaz, Aslam and Fry, Megan and Noonan, Anne M},
title = {Intracystic injection of large surface area microparticle paclitaxel for chemoablation of intraductal papillary mucinous neoplasms: Insights from an expanded access protocol},
journal = {Pancreatology},
year = {2024},
doi = {10.1016/j.pan.2023.12.014}
}
EUVIMED